baber/WOPTO huggingface dataset:
Patent NZ-522590-A (NZ)
Title: Vapour proof twisted pair cable including fibrous interstice filler
Inventor: DUPUIS MARC RAYMOND
IPC: H01B11/02
Filed: 2001-05-14
Abstract: A quad cable comprises: a jacket; at least one quad of insulated signal conductors enclosed within, and sealably engaging, the jacket, the insulated signal conductors contacting one another and arranged in a helix to define a hollow core and a pulled vapor proof material sealably engaging the insulated signal conductors, the vapor proof material substantially filling the hollow core along a length of the insulated signal conductors, the jacket and vapor proof material forming a hermetic seal surrounding the insulated signal conductors preventing vapor migration along a length of the insulated signal conductors. A vapor proof cable for carrying high speed data transmissions comprises: at least two signal conductors twisted in a helix configuration; a vapor proof pulled core filler pulled between the two signal conductors, the core filler being compressed and deformed to sealably fill at least internal interstices between the at least two signal conductors and a vapor proof pressure extruded peripheral material filling peripheral interstices located about the at least two signal conductors, the pulled core filler and extruded peripheral filler hermetically encasing the signal conductors along a length thereof to block vapor migration along the cable.
Patent NZ-523347-A (NZ)
Title: Optical apparatus with annular beam and focussing reflector for sperm particle irradiance analysis
Inventor: SHARPE JOHNATHAN
IPC: G02B27/20
Filed: 1997-01-31
Abstract: An analysation instrument (70) and method of using it is disclosed. The analysation instrument (70) includes an optical configuration adapted to produce an annular beam of electromagnetic radiation having a central axis or plurality of beams of electromagnetic radiation wherein said plurality of beams are evenly spaced from a central axis; and a focusing reflector (78) having an internal reflective surface having an optical axis and one or more foci, the reflector (78) being orientated to substantially receive, onto its reflective surface, the annular beam or the plurality of beams of electromagnetic radiation and an inspection zone overlapping one of the one or more foci for eventual analysis of a particle or object (80) located within the inspection zone (located at focus F).
Patent NZ-524607-A (NZ)
Title: Internal balloon seal for ostomy stoma
Inventor: MULHAUSER PAUL
IPC: A61F5/445
Filed: 2003-03-07
Abstract: A balloon-like member is received in the bowel and inflated to seal the stoma. The member includes a thin, flexible wall defining an opening. A rigid or semi-rigid cap retains the member and closes the opening in the member wall. Skin comfortable adhesive adheres the edge of the cap to the tissue surrounding the stoma. A flexible dilation tube facilitates insertion of the member and cooperates with a pump to inflate the member. The cap is preferably removeably attached to a standard two-piece ostomy faceplate and is provided with a filter element to vent flatus.
Patent NZ-526138-A (NZ)
Title: Teleconferencing system
Inventor: SUDO SATORU
IPC: H04M3/56
Filed: 2000-12-01
Abstract: A teleconferencing system that prevents misconnection between the teleconference terminal and a communication controller, and the use of the communication controller is optimized, and the conference condition can be set/modified through the teleconference terminal. Information about a first connection destination number is given to the teleconference terminal, and an ID number and password are given to each conference attendance. Information about the application of having a conference, the ID numbers and passwords of the conference attendances are recorded in a reception terminal when the reservation for the conference is made. When the application is accepted, the teleconference terminal sets up a connection to the reception terminal by using the first connection destination number and transmits the information about the ID numbers and passwords. The reception terminal determines a second connection destination number according to the result of collation of the ID numbers and passwords and transmits the information about the second connection destination number. The teleconference terminal sets up a connection to the communication controller by using the second connection destination number.
Patent NZ-528373-A (NZ)
Title: Hormone replacement therapy
Inventor: PICKAR JAMES HARRISON
IPC: A61P25/28
Filed: 2002-03-15
Abstract: Disclosed are pharmaceutical compositions comprising 0.2 mg to 0.1 mg of conjugated estrogens and 2.5 to 0.5 mg of medroxyprogesterone acetate. The compositions are used in the manufacture of medicaments for the treatment of menopausal or postmenopausal disorders.
Patent NZ-530004-A (NZ)
Title: Pyrrolidine derivatives as factor Xa inhibitors that have oral bioavailability and PK profiles suitable for acute and chronic thrombotic conditions
Inventor: CHAN CHUEN
IPC: C07D495/04
Filed: 2002-06-06
Abstract: Described are compounds of formula (I) and processes for their preparation, pharmaceutical compositions containing them and their use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated. wherein: R1 represents hydrogen, -C1-6alkyl, -C3-6alkenyl, or a group X-W, wherein X represents -C1-3alkylene and W represents -CN, -CO2H, -CONRbRc, -OCI-6alkyl, -CO2CI-6alkyl, phenyl or a 5-or 6-membered aromatic or non-aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, the phenyl or aromatic heterocyclic group being optionally substituted by one or more substituents selected from: -C1-3alkyl, -C1-3alkoxy, -C1-3alkylOH, halogen, -CN, -CF3, -NH2, -CO-H and OH; R2 and R3 is -C1-3alkyl or -CF3 and the other is hydrogen; Rb and Rc independently represent hydrogen or-C1-3alkyl; A represents a group selected from: Z represents one or two optional substituents independently selected from halogen and OH, W represents an optional substituent -C1-3alkyl, elk represents C2-3alkylene or C2-3alkenylene, T represents a heteroatom selected from O, S or N; B represents one or more optional substituents on ring carbon atoms selected from: (i) one or more substituents selected from -CF3, -F, -CO-H, -C1-6alkyl, -C1-6alkylOH, -(C1-3alkyl)NRbRc, -(C0 3alkyl)CONRbRc and -(C0-3alkyl)CO2C1-3alkyl, -CONHC2-3alkylOH, CH2NHC2-3alkylOH, -CH2OC1-3alkyl and -CH2SO2C1-3alkyl ; (ii) a group-Y-R Y represents -C1-3alkylene-, -CO-, -C1-3alkylNH-, -C1-3alkylNHCO-, -C1-3alkylNHSO2-, CH2NHSO2CH2-or a direct link, Re represents phenyl, a 5-or 6-membered cycloalkyl or a 5-or 6-membered heterocycle containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by one or more substituents selected from : -C1-3alkyl, -C1-3alkoxy, -C1-3alkylOH, halogen, -CN, -CF3, -NH2,-CO2H and -OH; or (iii) a second ring Rf, which is fused to the heterocyclic ring, wherein Rf represents phenyl, a 5-or 6-membered cycloalkyl group or a 5-or 6-membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, and the fused bicyclic group is optionally substituted by one or more substituents selected from:-C1 3alkyl, -C1-3alkoxy, -C1-3alkylOH, halogen, -CN, -CF3, -NH2,-CO2H and-OH; and pharmaceutical acceptable derivatives thereof.
Patent NZ-530055-A (NZ)
Title: Piperidine derivatives as NMDA receptor antagonists
Inventor: DOMANY GYORGY
IPC: A61P27/06
Filed: 2002-07-23
Abstract: Carboxylic acid amide derivatives of formula (I) are disclosed, wherein U, V, W, X, Y, Z, n and m are as defined as in the specification. Processes for producing of carboxylic acid amide compounds of formula (I), and the pharmaceutical manufacture of medicaments containing these compounds are also disclosed. These carboxylic acid amide derivatives of formula (I) may be suitable as highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.
Patent NZ-538223-A (NZ)
Title: Calcium receptor modulating compound and use thereof
Inventor: YASUMA TSUNEO
IPC: C07D487/04
Filed: 2003-08-21
Abstract: Disclosed is a compound of formula (IIIa) wherein the substituents are described in the specification. Also disclosed is the use of the compound of formula (IIIa) or a salt thereof in the manufacture of a medicament for preventing or treating disease caused by abnormality of calcium concentration in a living body or a calcium receptor.
Patent NZ-541963-A (NZ)
Title: Electrical connection device
Inventor: WELLS MARK
IPC: H01R13/639
Filed: 2004-01-20
Abstract: An electrical connection device (20), which comprises a socket (22) and a pin (24), is disclosed. The pin and the socket both have engagement surfaces, and one of them has a further surface that forms an angled wedging surface (36) for the device. One of the pin and the socket is secured in a housing (28). The pin and the socket are moveable relative to each other to form an electrical contact. The device further comprises a wedge portion (25), which is arranged to impart a force on the wedging surface by contacting it on movement to the engaged position within the housing. The pin and socket are arranged so that the engagement surfaces move into an opposing relationship on movement to the engaged position and the force imparted on the wedging surface biases one of the opposing engagement surfaces against the other engagement surface.
Patent NZ-542020-A (NZ)
Title: Tanning aids with a high protection factor
Inventor: SCHOCKE KAI-OLIVIER
IPC: C08K5/3492
Filed: 2004-03-02
Abstract: A tanning aid comprises a polymethyl methacrylate (PMMA) shaped body, where the transparency of the polymethyl methacrylate shaped body at 380 nm is at least 40%, and the polymethyl methacrylate shaped body comprises 0.005 to 0.4% by weight, based on the weight of the polymethyl methacrylate shaped body, of at least one triazine compound according to formula (I), wherein the substituents are as defined in the specification.
Patent NZ-543719-A (NZ)
Title: Pyrimidine derivatives for the treatment of abnormal cell growth
Inventor: KATH JOHN CHARLES
IPC: C07D401/14
Filed: 2004-12-08
Abstract: Disclosed are pyrimidine derivatives of forrmula 1 wherein the substituents are as defined in the specification. Derivatives of the type disclosed are non-receptor tyrosine kinase inhibitors, in particular of FAK, and are useful in the treatment of abnormal cell growth.
Patent NZ-547478-A (NZ)
Title: Washing machine provided with silver solution supply device
Inventor: LEE YOUNG SU
IPC: D06F39/08
Filed: 2004-04-16
Abstract: A washing machine comprising a tub, a water supply unit (17) for supplying water to the tub and a silver solution supply device (10) for supplying a silver solution to the tub, wherein the silver solution supply device includes a housing (11) provided with an inlet (13), installed at the opening (12) and an outlet (14), a water feed unit for connecting the inlet of the housing and the water supply unit of the washing machine, two silver members (15) installed in the housing and ionized by the electrolysis, and a current speed reduction member (16) positioned between an end of the silver member located at the outlet and the outlet of the housing. The current speed reduction member reduces the current speed of the wash water supplied to the silver solution supply device and changes the current of the wash water, thereby allowing the silver members to be sufficiently ionized and providing sufficient antibiotic and bactericidal effects.
Patent NZ-549426-A (NZ)
Title: Use of pyrimidine compounds in the preparation of parasiticides
Inventor: FRUCHTEL JORG
IPC: C07D239/46
Filed: 2005-03-07
Abstract: Disclosed are the use of 4,6 disubstituted 5-aminopyrimidine compounds of formula I for the control of insects of the order Acarnia on animals.
Patent NZ-549600-A (NZ)
Title: Frozen lactic acid bacteria culture of individual pellets
Inventor: STAVNSBJERG RIKKE
IPC: A23K1/00
Filed: 2005-02-24
Abstract: Disclosed is a pellet-frozen lactic acid bacteria (LAB) culture in a commercially relevant package that has a weight of at least 50g frozen material, wherein the frozen material is present in the form of individual pellets, having a content of viable bacteria of at least 109 colony forming units (CPU) per g frozen material and comprising from 0.5% to 13% of an additive compound measured as w/w of the frozen material, wherein the additive compound is an additive compound that is selected from the group of additive compounds consisting of Cyclodextrin, Maltitol, Trehalose, Fish gelatin, Maltodextrine, Yeast Extract and Spray gum, and which further is characterized by, when using an amount of 10% of the additive compound measured as w/w of the frozen material, the compound is able to increase the Tm' (onset temperature of ice melting) of the frozen lactic acid bacteria (LAB) culture, which without the additive compound has a Tm' value from -70 degrees C to -46 degrees C, to a Tm' value above -46 degrees C (measured by DSC) and wherein the frozen lactic acid bacteria (LAB) culture is characterized by that when stored at approximately -46 degrees C for 7-14 days the individual pellets of the frozen culture are not sticking together and therefore substantially remain as individual pellets where this is measured by following test the individual pellets of the frozen culture are pellet frozen in liquid nitrogen and 100 individual pellets (around 5-100 g of pellets) are poured into a petridish, thus forming a thin layer of loose individual single pellets, the layer being characterized in that the majority of the pellets are in physically contact with one or more of its neighbor pellets, placed at approximately -46 degrees C for 7-14 days and examined to see if the pellets are still loose or if the pellets had made clumps or are sticking together wherein the criteria for that the individual pellets of the frozen culture substantially remain as individual pellets are that at least 80 of the 100 individual pellets remain as loose individual single pellets; with the exception of a frozen lactic acid bacteria (LAB) culture that comprises LAB that are able to utilize sucrose and wherein the culture comprises cryoprotective agent compound selected from the group consisting of sucrose in an amount from 2% to 13% of sucrose measured as w/w of the frozen material; and trehalose in an amount from 4% to 6% of trehalose measured as w/w of the frozen material; and a trehalose/sucrose mixture both in the amount of 13% measured as w/w of the frozen material. The pellet-frozen LAB culture can be used to make a food or feed product.
Patent NZ-560567-A (NZ)
Title: Sling with predictable pre-failure warning indicator
Inventor: ST GERMAIN DENNIS
IPC: B66C1/12
Filed: 2006-05-19
Abstract: A pre-failure warning indicator (11) is provided for use with a sling (10). The pre-failure warning indicator triggers at a point that is predictable within a relatively narrow range, thereby increasing the possibility that a damaged sling is removed from use. The pre-failure warning indicator includes a dedicated strand of material (20) that is placed in close proximity to the load-bearing core yarns (17) of the sling but remains separate and independent from the core yarns; the ends (22,24) of the dedicated strand are connected via a sacrificial "ring" (26). A warning fibre (29) having an end that is visible to operators/riggers works in conjunction with the sacrificial strand and the ring. The ring is designed to fail when the sling is subjected to a specifically chosen condition (e.g., excessive weight). The failure of the ring causes the warning fibre to withdraw from the rigger's view thereby warning the rigger that the sling was subjected to the specifically chosen condition and may be damaged.
Patent NZ-562381-A (NZ)
Title: Haemophilus influenzae type B
Inventor: MASIGNANI VEGA
IPC: C12N15/74
Filed: 2006-03-30
Abstract: Provided are Haemophilus influenzae antigenic polypeptides having specified sequences, or variants with at least 75% sequence identity. The peptides are useful in medicaments to prevent or alleviate H. influenzae infections.
Patent NZ-573443-A (NZ)
Title: Low dose sublingual tablets of opioid analgesics and preparation process
Inventor: HERRY CATHERINE
IPC: A61K9/20
Filed: 2007-06-08
Abstract: Disclosed is a sublingual tablet comprising less than 20mg/tablet of an opioid analgesic suitable for sublingual administration, comprising a directly compressible diluent in the form of neutral cores, wherein said neutral cores are essentially spherical granules comprising sucrose and starch, and wherein said neutral cores are coated with at least one active layer comprising less than 5 percent by weight of the neutral core of said opioid analgesic suitable for sublingual administration.
Patent NZ-573976-A (NZ)
Title: New 1H-indol-1-YL-urea compounds, a process for their preparation and pharmaceutical compositions containing them
Inventor: BRION JEAN-DANIEL
IPC: A61K31/17
Filed: 2008-12-24
Abstract: Disclosed is a compound of formula (I) wherein the substituents are disclosed within the specification. Also disclosed is the use of the above compound in the manufacture of a medicament for use in the treatment of depression, anxiety, disorders of memory in the course of ageing and/or neurodegenerative diseases, and in the palliative treatment if Parkinson's disease, and for adaption to stress.
Patent NZ-580660-A (NZ)
Title: Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
Inventor: JUDD ANDREW S
IPC: A61P3/04
Filed: 2008-04-30
Abstract: Disclosed herein are compounds of formula (I), wherein G1 is phenyl or pyridinyl, and the other substituents are as defined within the specification, processes for its preparation and uses thereof. Said compounds are useful as inhibitors of diacylglycerol O-acyltransferase type 1 (DGAT-1) enzyme and are therefore useful in the treatment of diseases related thereof, such as type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease.
Patent NZ-582321-A (NZ)
Title: System for distributing a fluid via a packing in which the fluid trickles from the top to the bottom
Inventor: DAUM KARL-HEINZ
IPC: B01D53/18
Filed: 2008-07-11
Abstract: Disclosed is a system for distributing a fluid via a filler packing (PA) or other structured packing, in which the fluid can trickle from the top to the bottom. The system has a container accommodating the packing. A distributor channel (2) has a substantially closed but ventable chamber (7) in which a pressure corresponding to the pressure existing in the container accommodating the packing can be maintained, and has at least one outlet slot (3) of predetermined width at its lower end (4) and a guide member (5). At least one distributor member (1) is arranged above the packing and comprises nozzles through which the fluid is dischargeable into the chamber of the distributor channel. The distributor channel downwardly adjoins the distributor member and its width does not significantly exceed the diameter of the distributor member. The distributor member constitutes a pressure conduit from which the fluid is introduceable via openings into the ventable chamber of the distributor channel, such that below the openings a specified fluid level is obtained in the distributor channel. The fluid is dischargeable from the distributor channel via the at least one outlet slot to the filler packing.
Patent NZ-587469-A (NZ)
Title: Insertion device with a moving part attached to the needle that moves in a different direction from the needle
Inventor: GYRN STEFFEN
IPC: A61M5/142
Filed: 2009-02-19
Abstract: An insertion device comprising a penetrating member 50 comprising an insertion needle connected to transformation means 52, which penetrating member 50 before and during insertion is attached to a body holding a cannula or a sensor which body comprises retention means securing the body and the cannula or sensor at a surface of insertion after insertion has taken place, a moving part 38 comprising guiding means 39 which guiding means 39 restrict the movement of the transformation means 52 and guide the penetrating member 50 from a first to a second position in a first direction, i.e. the direction of insertion, towards the injection site, and a stationary housing 30 comprising guiding means 39 which guiding means 39 restrict the movement of the moving part 38. The guiding means 39 guide the moving part 38 in a second direction which is linear and different from the first direction i.e. the direction of insertion.
Patent NZ-591782-A (NZ)
Title: Rock drill bit with three spiral flutes and a single blade tip that extends beyond the drill axis with chip forming teeth
Inventor: KERSTEN HEINRICH
IPC: B23B51/02
Filed: 2009-09-03
Abstract: 591782 Disclosed is a rock drill bit for increased drilling progress. The drill bit comprising a shank fitted with a clamping end and a drilling tip at the end away from the clamping end, the drilling tip comprising three blades which are alar in topview. The blades each comprise at their top side a lip constituted by a leading chipping face and a trailing flank, the lips substantially converging onto each other within a central zone centred on the drill bit axis. In the central zone, a single long lip runs through the bit axis or runs a distance laterally offset from and past the bit axis and comprises a commensurate overshoot segment extending beyond the bit axis that in the vicinity of the bit axis. The long lip constitutes a chisel edge and in that the chisel edge comprises two radially outer ends axially projecting from the in-between centre of the chisel edge.
Patent NZ-593437-A (NZ)
Title: Use of the association of ivabradine and perindopril in the treatment of heart failure
Inventor: THUILLEZ CHRISTIAN
IPC: A61P43/00
Filed: 2011-06-13
Abstract: Disclosed is the use of ivabradine also known as 3-{ 3-[{ [(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-methyl} (methyl)amino]propyl} -7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms and perindopril also known as (2S,3aS,7aS)-1-[(2S)-2-{ [(2S)-1-ethoxy-1-oxopentan-2-yl]amino} propanoyl]-octahydro-1H-indole-2-carboxylic acid or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms, for the manufacture of a medicament for the treatment of heart failure with preserved systolic function.
Patent NZ-594426-A (NZ)
Title: A membrane pump head for a homogenizer or a high-pressure pump
Inventor: JOHANSSON CLAES-GORAN
IPC: A01J11/16
Filed: 2010-02-16
Abstract: 594426 Disclosed is a membrane pump head (1) for a homogenizer or a high-pressure pump that allows improved seal service life and higher pump pressures. The membrane pump head comprises at least one pump head enclosed in a pump housing (2). The membrane pump head also includes a product chamber (3) with inlet (see 20, figure 3) and outlet (see 7, figure 3) for the product, as well as a hydraulic chamber (4) in which a piston (9) is disposed to operate. The product chamber and the hydraulic chamber are separated by a double membrane (5). The double membrane is oriented at an angle of 15-75º in relation to the longitudinal direction of the piston.